Supplementary data from Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Table 1. Clinical characteristics of non-APL AML patients with MRD data Supplemental Table 2. Flow cytometry panel for MRD Supplemental Table 3. Proportions of AML blasts, CD34+ cells, and CD123+ cells at diagnosis and in remission in 86 patients with AML Supplemental Table 4. Logistic regression models for predictive factors of MRD Supplemental Table 5 A&B. Multivariate Analysis for time to relapse (TTR) Supplemental Table 6. Cytotoxicity of SL-101 in myeloid leukemia cell lines Supplemental Table 7. Demographic and disease characteristics of AML patients for in vitro and in vivo tests Supplemental Figure 1. Gating strategy of CD34+CD123+ blasts in bone marrow samples collected at diagnosis and in remission. Supplemental Figure 2. Expression levels of CD123 and CD131 do not correlate with in vitro response to SL-101 in primary AML samples. Supplemental Figure 3. Phenotypes of primary AML samples post SL-101 treatment. Supplemental Figure 4. SL-101 suppresses AML colony formation but spares normal counterparts. Supplemental Figure 5. SL-101 targets AML leukemia-initiating cells in vivo.
Authors: Lina Han, Jeffrey L. Jorgensen, Chris Brooks, Ce Shi, Qi Zhang, Graciela M. Nogueras González, Antonio Cavazos, Rongqing Pan, Hong Mu, Sa A. Wang, Jin Zhou, Gheath AI-Atrash, Stefan O. Ciurea, Mike Rettig, John F. DiPersio, Jorge Cortes, Xuelin Huang, Hagop M. Kantarjian, Michael Andreeff, Farhad Ravandi, Marina Konopleva
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361885237